GlassScriptPhysician profile
Junjing Guo
NPI 1700348984
$3,028.06
in general payments reported to CMS, 2019-2025
24 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $376 · 2024: $708 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $735.21 | 2023-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $423.03 | 2024-2025 | Tagrisso, Calquence |
| Recordati_rare_diseases_inc. | $306.89 | 2025 | Sylvant |
| Amgen INC. | $240.88 | 2024-2025 | Blincyto, Blincyto |
| Janssen Biotech, INC. | $191.71 | 2025 | Rybrevant, Carvykti, Darzalex |
| Alexion Pharmaceuticals, INC. | $186.42 | 2024-2025 | Ultomiris |
| Pfizer INC. | $153.72 | 2025 | |
| Incyte Corporation | $148.50 | 2025 | Jakafi |
| Servier Pharmaceuticals LLC | $146.68 | 2025 | |
| Springworks Therapeutics, INC. | $58.73 | 2025 | Gomekli |
| Sumitomo Pharma America, INC. | $50.87 | 2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $45.81 | 2025 | |
| Taiho Oncology, INC. | $45.36 | 2025 | |
| Celgene Corporation | $41.81 | 2025 | Reblozyl |
| Jazz Pharmaceuticals INC. | $36.32 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $31.42 | 2025 | Mektovi, Tukysa, Braftovi |
| Daiichi Sankyo INC. | $29.08 | 2025 | Enhertu |
| Syndax Pharmaceuticals, INC. | $27.45 | 2025 | Revuforj |
| Takeda Pharmaceuticals U.S.A., INC. | $26.17 | 2025 | Fruzaqla |
| Eisai INC. | $24.88 | 2025 | |
| Exelixis INC. | $23.23 | 2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $22.98 | 2025 | Pyrukynd |
| Puma Biotechnology, INC. | $16.24 | 2025 | |
| Genentech USA, INC. | $14.67 | 2025 | Itovebi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junjing Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.